These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 3939152)

  • 41. Assessing the introduction of universal varicella vaccination in the Netherlands.
    Boot HJ; de Melker HE; Stolk EA; de Wit GA; Kimman TG
    Vaccine; 2006 Sep; 24(37-39):6288-99. PubMed ID: 16790302
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Chickenpox vaccines: new drugs. A favourable risk-benefit balance in some situations.
    Prescrire Int; 2005 Jun; 14(77):85-91. PubMed ID: 15977369
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States.
    Ortega-Sanchez IR; Meltzer MI; Shepard C; Zell E; Messonnier ML; Bilukha O; Zhang X; Stephens DS; Messonnier NE;
    Clin Infect Dis; 2008 Jan; 46(1):1-13. PubMed ID: 18171206
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A combination measles, mumps, rubella, and varicella vaccine (ProQuad) given to 4- to 6-year-old healthy children vaccinated previously with M-M-RII and Varivax.
    Reisinger KS; Brown ML; Xu J; Sullivan BJ; Marshall GS; Nauert B; Matson DO; Silas PE; Schödel F; Gress JO; Kuter BJ;
    Pediatrics; 2006 Feb; 117(2):265-72. PubMed ID: 16452343
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Chickenpox: sufficient reasons for the introduction of vaccination].
    Rümke H; de Groot R
    Ned Tijdschr Geneeskd; 2006 Dec; 150(48):2630-2. PubMed ID: 17205937
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Critical prevalence of antibodies minimizing vaccination costs for hepatitis A, hepatitis B, varicella, measles and tetanus in adults and adolescents in Catalonia, Spain.
    Plans-Rubió P
    Vaccine; 2004 Sep; 22(29-30):4002-13. PubMed ID: 15364450
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Estimate of the cost/benefit ratio of measles vaccination].
    Cárdenas Ayala VM; Ruiz Matus C; Cabrera Coello L; Montesano Castellanos R; Garrido Lozada MT; Olvera Castillo R; Díaz Ortega JL
    Salud Publica Mex; 1989; 31(6):735-44. PubMed ID: 2516660
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cost-effectiveness of a routine varicella vaccination program for US children.
    Lieu TA; Cochi SL; Black SB; Halloran ME; Shinefield HR; Holmes SJ; Wharton M; Washington AE
    JAMA; 1994 Feb; 271(5):375-81. PubMed ID: 8283587
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Benefit-cost analysis of rubella vaccination policy.
    Schoenbaum SC; Hyde JN Jr Bartoshesky L; Crampton K
    N Engl J Med; 1976 Feb; 294(6):306-10. PubMed ID: 813141
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Costs and benefits of measles and mumps immunization in Austria.
    Wiedermann G; Ambrosch F
    Bull World Health Organ; 1979; 57(4):625-9. PubMed ID: 118811
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cost effectiveness of vaccination strategies in adults without a history of chickenpox.
    Smith KJ; Roberts MS
    Am J Med; 2000 Jun; 108(9):723-9. PubMed ID: 10924649
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Costs and benefits of routine varicella vaccination in German children.
    Beutels P; Clara R; Tormans G; Van Doorslaer E; Van Damme P
    J Infect Dis; 1996 Nov; 174 Suppl 3():S335-41. PubMed ID: 8896542
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The cost-effectiveness of routine childhood varicella vaccination in Germany.
    Banz K; Wagenpfeil S; Neiss A; Goertz A; Staginnus U; Vollmar J; Wutzler P
    Vaccine; 2003 Mar; 21(11-12):1256-67. PubMed ID: 12559807
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cost containment analysis of childhood vaccination against varicella in Israel.
    Ginsberg GM; Somekh E
    J Infect; 2004 Feb; 48(2):119-33. PubMed ID: 14720487
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A cost-benefit analysis of varicella vaccination in Aragón.
    Peña Blasco G; Blasco Pérez-Aramendía MJ
    Arch Argent Pediatr; 2017 Oct; 115(5):432-438. PubMed ID: 28895689
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Chickenpox: An update.
    Lo Presti C; Curti C; Montana M; Bornet C; Vanelle P
    Med Mal Infect; 2019 Feb; 49(1):1-8. PubMed ID: 29789159
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Social and economic impact of chicken pox vaccine at 15 months of age. Castile and Leon, Spain, 2004].
    Pérez-Rubio A; Castrodeza Sanz JJ; Gil Costa M; Luquero Alcalde FJ; Eiros Bouza J; Ortiz de Lejarazu R
    Rev Esp Salud Publica; 2008; 82(1):101-9. PubMed ID: 18398555
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Varicella among seafarers: a case study on testing and vaccination as a cost-effective method of prevention.
    Idnani N
    Int Marit Health; 2010; 61(1):32-5. PubMed ID: 20496326
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A benefit-cost analysis of mumps vaccine.
    Koplan JP; Preblud SR
    Am J Dis Child; 1982 Apr; 136(4):362-4. PubMed ID: 6803581
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Controlling varicella in the healthcare setting: the cost effectiveness of using varicella vaccine in healthcare workers.
    Nettleman MD; Schmid M
    Infect Control Hosp Epidemiol; 1997 Jul; 18(7):504-8. PubMed ID: 9247834
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.